LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Distinct Mutation Patterns Identified in Appendiceal Cancer

By LabMedica International staff writers
Posted on 24 Dec 2020
Print article
Image: Histopathology of dissected appendiceal tissue showing moderately differentiated neoplastic glands lined by cells with nuclear pleomorphism and hyperchromasia (Photo courtesy of Pacific Northwest University of Health Sciences).
Image: Histopathology of dissected appendiceal tissue showing moderately differentiated neoplastic glands lined by cells with nuclear pleomorphism and hyperchromasia (Photo courtesy of Pacific Northwest University of Health Sciences).
The incidence of appendiceal cancer (AC) is rising, particularly among individuals younger than 50 years (early-onset AC), with unexplained etiologies. The unique spectrum of somatic cancer gene variations among patients with early-onset AC is largely undetermined.

Appendiceal cancer is a rare neoplasm, with an age-adjusted incidence rate of 0.97 per 100,000. The incidence of appendiceal cancer has increased by 54%. Histologically, this malignancy accounts for 0.5%-1% of all biopsy specimens following appendectomies. Most patients will present with distant metastatic disease with significant tumor burden in the peritoneum, placing them at higher risk for bowel obstruction and increased morbidity and mortality.

Medical Scientists at the Vanderbilt University Medical Center (Nashville, TN, USA) included in a cohort study individuals aged 18 years and older diagnosed with pathologically verified AC. In total 385 individuals (mean ± SD) age at diagnosis, 56.0 ±12.4 years; (187 [48.6%] men; 306 [79.5%] non-Hispanic White individuals) with AC were included in this study, and 109 patients (28.3%) were diagnosed with early-onset AC. Somatic variation data in tumor tissues was generated using clinical-grade targeted gene panel sequencing approaches from different sequencing centers. Median sequencing depth (pooled median read depth, 500×) was determined.

The investigators reported that in contrast to late-onset cases, which tended to be marked by recurrent, non-silent alterations in the GNAS gene, they saw a significant dip in GNAS variants in tumors from individuals with early-onset disease. Instead, appendiceal cancer tumors from the younger patients tended to contain more non-silent variants in genes such as PIK3CA, SMAD3, and TSC2.

Compared to the corresponding late-onset cases, the team documented declines in GNAS mutations from early-onset appendiceal cancers from both the mucinous and non-mucinous histological subtypes of appendiceal adenocarcinoma, though the proportion of those variants differed slightly by subtype. In the sample set considered, the investigators only detected GNAS gene mutations in early- and late-onset tumors lacking TP53 mutations, while TP53 mutations were limited to GNAS mutation-free tumors, suggesting these changes are likely mutually exclusive.

Xingyi Guo, PhD, an assistant professor of medicine and senior author of the study, said, “Appendiceal cancer diagnosed among younger individuals harbored a distinct genomic landscape compared with appendiceal cancer diagnosed among older individuals. Development of therapeutic modalities that target these unique molecular features may yield clinical implications specifically for younger patients.”

The authors concluded that their study had found a distinct spectrum of somatic variations among early-onset AC cases, as younger patients had higher odds of presenting with PIK3CA, SMAD3, and TSC2 somatic variations and decreased odds of presenting with GNAS variations compared with late-onset AC cases. These findings demonstrate that ACs diagnosed among young individuals harbor a distinct molecular phenotype compared with late-onset ACs.

The study was published on December 9, 2020 in the JAMA Network Open.

Related Links:
Vanderbilt University Medical Center

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.